Biotech Stocks
Cellares links with GenomeFrontier to test automation approach for virus-free CAR-Ts
FiercePharma
1h ago
Cellares is partnering with Taiwanese biotech GenomeFrontier Therapeutics to evaluate the integrated contract developer and manufacturer’s cell shuttle platform for use in the production of virus-free CAR-T therapies.
Discussion
Sign in to join the discussion. Comments loading…